Sign In
Buy TRCK
$0.640
+0 (+0%)
At Close: Jun 03, 2026
US IPO Activity On Track For Best Quarter Since Q1 2022
10:24am, Tuesday, 16'th Sep 2025
Last week's barrage of IPO activity continues this week with expected debuts from Stubhub and Netskope. According to our IPO data, licensed from IPOScoop, six companies IPO'd last week, kicking off
FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
08:00am, Tuesday, 16'th Sep 2025
NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced to
1 st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR 1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $
Is Carnival Stock on Track to Return to Pre-COVID Highs?
08:00pm, Wednesday, 10'th Sep 2025
Carnival (CCL -0.65%) was once sailing in very choppy waters. The company was facing a lot of uncertainty when the COVID-19 pandemic hit.
Mo's Smoke-Free Vision vs. Cigarette Declines: Is Transition on Track?
11:56am, Wednesday, 10'th Sep 2025
Altria shows cigarette volumes sliding while on! nicotine pouches surge in the second quarter, spotlighting the gradual shift toward smoke-free growth.
Berkshire Hathaway: Impressed By G. Abel's Track Record
07:04am, Wednesday, 10'th Sep 2025
Warren Buffett's planned departure and Greg Abel's succession have raised investor concerns, contributing to Berkshire's 20% underperformance vs. the market. Abel has delivered ~12% returns at Berkshi
Is Modine on Track to Reach $2B in Data Center Revenues by 2028?
12:01pm, Tuesday, 09'th Sep 2025
MOD targets $2B in data center revenues by 2028 with a $100M U.S. expansion plan focused on capacity growth and innovation.
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
01:58pm, Monday, 08'th Sep 2025
While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics a
Societe Generale: On Track To Achieve 2026 Financial Targets
02:12am, Sunday, 07'th Sep 2025
Societe Generale has benefited from recent profitability improvements in French retail and mobility/international retail segments. At the same time, the Capital Markets/Investor Solutions segment did
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
08:00am, Friday, 05'th Sep 2025
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program
3 Growth Stocks on Track to Reach a $300 Billion Valuation by 2026
05:50am, Friday, 05'th Sep 2025
While there is a lot of talk and attention focused on trillion-dollar companies, the fact of the matter is that, as of Sept. 3, only 34 publicly traded companies (out of more than 10,500 international
Gold (XAU/USD) Price Forecast: Rally Pauses, Weekly Breakout Still on Track
04:58pm, Thursday, 04'th Sep 2025
Gold eased Thursday, dipping toward $3,500 support after reaching $3,578 Wednesday. Despite the pullback, weekly and monthly signals confirm strong demand, keeping higher breakout targets in play.
STOCKHOLM , Sept. 2, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics Lic
Chipotle's Margins Slip: Can $4 Million AUV Goal Stay on Track?
10:46am, Monday, 01'st Sep 2025
CMG's margins are down in the second quarter, but efficiency upgrades and catering expansion can be a key to sustaining its $4 million AUV target.
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track Designation
11:47am, Tuesday, 26'th Aug 2025
Allarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D
